Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | KDM5C | P41229 | 2/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188311 | 0.95 | ECE1 (0.56) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL19607968 | 0.85 | ATM (0.53) | ECE1KDM4ELMNATSHRPRMT1 | |
| SCHEMBL9717468 | 0.83 | ECE1 (0.81) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL9717431 | 0.83 | ECE1 (0.65) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL13465545 | 0.81 | EPHX2 (0.49) | FAAHCNR1CNR2KDM4ELMNA | |
| SCHEMBL8531287 | 0.81 | ECE1 (0.62) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL27858651 | 0.81 | ECE1 (0.70) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL1156656 | 0.80 | ALDH1A1 (0.41) | ECE1KDM4EEGLN1KDM5CPHF8 | |
| SCHEMBL9717382 | 0.79 | ECE1 (0.60) | ECE1FAAHCNR1CNR2LMNA | |
| SCHEMBL9717391 | 0.79 | ECE1 (0.60) | ECE1FAAHCNR1CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | ECE1 1541/4885FAAH 1445/4885CNR1 3828/4885 |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | ECE1 531/4885FAAH 2479/4885CNR1 122/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | ECE1 531/4885FAAH 2479/4885CNR1 122/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | ECE1 635/4885FAAH 1736/4885CNR1 78/4885 |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, ADORA2B, TBXA2R | ECE1 591/4885FAAH 2392/4885CNR1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.